Our Tech

A unified drug design engine for a new era of discovery

‍

Redefining drug discovery

The AI technology we have developed allow our researchers to explore a new chemical landscape. We can now take on historically challenging targets with extraordinary pace and accuracy.

A heritage of breakthroughs

Isomorphic Labs was launched from DeepMind, and many of our team contributed to the creation of the groundbreaking AlphaFold system.

Here to solve all disease

Our interdisciplinary team has developed a unified, state-of-the-art drug design engine that will transform how we design new drugs, and ultimately change the way medicine will help and heal people.

“I believe there is no more important application for AI than helping to improve human health.”

SIR DEMIS HASSABIS

FOUNDER AND CEO

Isomorphic Labs’ unified drug design engine

Where others may build solutions around a specific design target, Iso’s drug design engine is built on AI models capable of working across multiple therapeutic areas and drug modalities.

Digital speed

Our pioneering AI-first approach means much of the time-consuming experimental work previously associated with identifying a drug candidate at the bench in a lab, can now be conducted much more quickly and efficiently ‘in silico’: on a computer.

Unprecedented opportunity

This is unlocking exciting opportunities for Iso’s scientists to probe new chemical space, explore previously intractable targets with strong disease associations, and design new drug candidates with much greater pace and precision.

Breakthrough pipeline

Iso’s breakthrough technology has helped to expand our drug discovery programs from small molecules to biologics and beyond. In addition to our partnered programs, we are also developing an internal drug candidate pipeline focused in oncology and immunology.

Universal engine

We developed and released AlphaFold 3 in May 2024. This latest generation model allows researchers to model the structures and interactions of all of life’s molecules with unprecedented accuracy. But to create a truly generalisable drug design engine, we have developed multiple further breakthroughs that tackle the full spectrum of complexity in drug design. This allows our AI drug design engine to operate end-to-end, in a way that is both target and disease agnostic.

Superior data

Our ‘dataverse’ - a unique, curated collection of life science data, powers a cutting-edge research environment capable of running massive volumes of in-silico experiments across vast GPU fleets. This infrastructure ensures our model performance continues to scale exponentially. By grounding this technology in the craft of drug design, we’ve built an interface that puts the full power of our multi-modality AI engine directly into the hands of scientists to accelerate discovery.

Interdisciplinary Expertise

Our models are developed, crafted and employed by our world-leading, interdisciplinary team of machine learning researchers and engineers, software developers, medicinal chemists, computational chemists and biologists, who are building on pioneering breakthroughs like AlphaFold.

Latest from Iso

Announcement

Everything interesting happens at the intersection

Iso’s success relies on our brilliant teams working together, learning from and empowering each other every single day.

Machine Learning Research &
Engineering

Drug Design &
Medical Research

People &
Operations

MAX JADERBERG

CHIEF AI OFFICER

“AlphaFold 3 was a major leap forward in understanding biological structures. But we know we’re never going to solve drug design with AlphaFold alone. We’ll need half a dozen more breakthroughs of that magnitude to reach our ambitious goal. Our progress in the field is rapidly advancing. We’re well on the way to getting there.”

Agnieszka Podsiadlo

Head of Engineering

“At Isomorphic Labs, being on the cutting edge of technology and seeing what our AI models can do feels like magic. Not many people can say they’re waking up, tackling diseases, and having fun doing it! If anyone is going to crack this and redesign how drugs are made, it’s going to be Iso.”

Catherine Tong

Senior Research Scientist, AI

“Every person here, regardless of level or expertise, is motivated by our mission to improve drug discovery and to break down traditional siloes, working in an interdisciplinary way to achieve our ambition. It’s energising and inspiring to work this way every day.”